BCR-ABL oncogene, the molecular hallmark of chronic myelogenous leukemia (CML) arises in a primitive hematopoietic stem cell with both differentiation and self-renewal ability. To study the phenotypic effects of BCR-ABL in a clonal in vitro self-renewal and differentiation model, we have introduced BCR-ABL in the ES cell line CCE. The major effect of BCR-ABL expression was the persistence of primitive morphology of ES cells despite LIF deprivation, correlated with a constitutive activation of STAT3, the major self-renewal factor of ES cells, but no evidence of activation of STAT5. The enforced expression of BCR-ABL in an ES cell line, engineered to express a tetracycline-inducible dominantnegative form of a STAT3, triggered ES cell differentiation with an increased generation of hematopoietic cells expressing erythroid and megakaryocytic phenotypes. RT-PCR analysis for Oct4, Brachyury and b-globin expression confirmed a delay of differentiation in BCR-ABL expressing clones, which could be entirely reversed upon activation of the dominant-negative form of STAT3. To study the possible relevance of STAT3 activation by BCR-ABL in human CML, Western blot analyses performed on the CD34 þ cells, purified from CML patients at different stages of their disease, also demonstrated increased levels of STAT3 proteins phosphorylated both on tyrosine and serine residues. These results represent to our knowledge the first functional link between BCR-ABL oncogene and a self-renewal in the context of ES cells through constitutive activation of STAT3. Thus, the BCR-ABL embryonic stem cell model that we developed as well as the results obtained in human CML samples suggests a role for STAT3 in the pathogenesis of human CML.
Introduction
The Philadelphia chromosome (Ph1) is the hallmark of chronic myelogenous leukemia (CML), a clonal malignancy of the pluripotent hematopoietic stem cell (Clarkson et al., 1997) . The molecular counterpart of the Ph1 chromosome is the chimeric fusion gene bcr-abl, generating the p210 BCR-ABL protein responsible for the development of CML (Groffen et al., 1984; Konopka et al., 1984; Shtivelman et al., 1985) . The two major characteristics of CML at the level of hematopoietic stem cell biology are the involvement of a very primitive quiescent stem cell (Holyoake et al., 1999) and an unperturbed terminal differentiation towards all lineages during the chronic phase which may last for several years (Sawyers, 1999) . Mice models of CML have allowed the demonstration of the responsibility of BCR-ABL at the origin of hematopoietic transformation (Daley and Baltimore, 1988; Daley et al., 1990; Huettner et al., 2000) , but could not reproduce the progression of the disease from chronic phase to blast phase. Animal models, as well as clinical observations, suggest that BCR-ABL expression is associated with both an expansion of a differentiating myeloid cell compartment and an inhibition of differentiation process during the acute phase (Sawyers, 1999) .
In order to investigate the molecular events in the early steps of BCR-ABL-associated hematopoiesis, we wished to use the murine ES cells that present the advantage of reproducing the cellular steps occurring during the initiation of hematopoiesis from an undifferentiated embryonic stem cell compartment. The previous work by the use of BCR-ABL gene transfer in ES cells showed the ability of BCR-ABL to induce a hematopoietic proliferative potential when BCR-ABL was expressed at the stage of embryoid bodies, induced by LIF withdrawal from ES cell cultures (Era and Witte, 2000; Perlingeiro et al., 2001) . The study of the effects of BCR-ABL oncogene at the very early stages of ES cell development has not been performed so far. The ability to express BCR-ABL in the context of a multipotent primitive cell with hematopoietic potential offers the advantage of studying the effects of the fusion oncogene before, during and after the transition to the hematopoietic stage in a well-controlled, clonal in vitro differentiation system.
Results

BCR-ABL-expressing ES cell exhibit delayed differentiation in response to LIF withdrawal
After BCR-ABL gene transfer into CCE cells, PCR analysis at the DNA level allowed the identification 60 ES cell clones with BCR-ABL integration. Out of these 60 clones, 12 were found to express BCR-ABL protein and four were selected for functional analysis. Variable levels of BCR-ABL protein were found to be present in all four clones ( Figure 1a ). The propagation of ES cells through different passages did not lead to any decrease in BCR-ABL expression (data not shown).
We then asked whether the behavior of the BCR-ABL-expressing ES cell clones would change their growth or differentiation patterns upon LIF deprivation in liquid culture. For this purpose, ES-BCR-ABL clones and the NeoR-control cells growing on the embryonic fibroblast layers and exogenous LIF were trypsinized. The cell suspension containing the ES cells and contaminating fibroblasts were placed on plastic dishes for 2 h to induce adhesion of the latter. Nonadherent ES cells were then placed in tissue culture dishes in the absence of stroma but in the presence or in the absence of LIF. This condition was chosen in order to be able to detect any morphological changes that might occur in the absence of both stromal feeder and LIF. The medium was changed each day and the clones were morphologically evaluated at day 3.
As shown in Figure 1d , in the absence of LIF, the ESNeoR cells rapidly became flattened and underwent morphological differentiation evidenced by the appearance of epithelial and fibroblast-like cells leading to the destruction of the characteristic three-dimensional ES cell structures. In contrast, all BCR-ABL-expressing clones exhibited a remarkable preservation of the compact ES cell structures during this period in the absence of LIF, a pattern similar to that seen in these cells in the presence of LIF (Figure 1d ). Similar results were observed in the four other BCR-ABL-expressing ES cell clones (data not shown), confirming that absence of differentiation was consistently associated with BCR-ABL expression.
BCR-ABL constitutively activates STAT3 in ES cell clones
Activation of the latent transcription factor STAT3 has been shown to play a central role in the maintenance of the pluripotent ES cell phenotype (Niwa et al., 1998) . Inhibition of cell differentiation could thus be because of a constitutive activation of STAT3 molecule. To evaluate this possibility, EMSA were performed with the various ES cells transfectants. As can be seen in Figure 1b , NeoR-control cells grown for 3 days in the (Figure 1b, lanes 1a, 1c) . These cells underwent differentiation as described above (Figure 1d ). When the same cells were grown in the presence of LIF for 3 days, they remained undifferentiated and a clear STAT3 activation was observed both in the presence and in the absence of feeder layers (lanes 1b and 1d) . In contrast, when ES cells expressing the BCR-ABL transgene (clone c16) were grown for 3 days in the absence of LIF, they exhibited a strong STAT3 DNAbinding activity (Figure 1b, lane 2a) . When the same cells were maintained in the presence of LIF, an even stronger STAT3 DNA-binding activity was observed in all conditions tested (Figure 1b, lanes 2b and 2d) . By Western blot analysis, we found that STAT3 was strongly phosphorylated on both Tyr705 and Ser727 residues in ES cells expressing BCR-ABL. Moreover, in these cells, STAT3 level was increased as compared to NeoR cells (Figure 1c) . In a second series of experiments, BCR-ABL clones growing in the presence of LIF and feeders (c9, d12, c16, e23) were washed with PBS twice and cultured in the absence of LIF and feeders for 24 h before performing nuclear extracts. In these conditions, a high STAT3 activation was evident in all four BCR-ABL-expressing clones tested, while no activation was detected in NeoR cells (Figure 1b , lanes 3a-7a). Antibody supershift experiments indicated that the DNA-binding complex consisted exclusively of STAT3 homodimers (lane 7c) with no activation of STAT1 being detectable (lane 7b) in any BCR-ABLexpressing clone. These observations indicate that BCR-ABL induced a constitutive activation of STAT3 in the context of ES cells, which is further increased by the addition of LIF. BCR-ABL has previously been reported to trigger the preponderant activation of STAT5 in hematopoietic cells (Carlesso et al., 1996; Ilaria and Van Etten, 1996) . We therefore tested the activation status of STAT5 in our BCR-ABL ES transfectants. Interestingly, although Western blot analyses showed significant amounts of STAT5 in all BCR-ABL ES transfectants, the use of phosphospecific STAT5 antibody did not show any detectable phospho-STAT5. Similarly, gel-shift analyses using the canonical STAT5-responsive b-casein probe did not show any evidence of constitutive STAT5 activation in BCR-ABL-expressing ES cells (data not shown). Thus, these findings suggested that BCR-ABL induced a specific and elective activation of STAT3 in the context of ES cells.
Inhibition of ES cell differentiation by BCR-ABL can be reverted by abrogation of STAT3 activation
Since BCR-ABL is known to activate a variety of signaling pathways, STAT3 activation might not be the crucial factor responsible for the differentiation block observed in BCR-ABL transfectants. In order to demonstrate the specific involvement of STAT3 signaling in this phenomenon, we used an ES cell line expressing a dominant-negative form of STAT3 transgene, STAT3F, under the control of a tetracyclineresponsive promoter, namely the GS2 ES cell line, as described by Niwa et al. (1998) . We introduced BCR-ABL transgene in this clone by means of retroviral transduction using the MIGR-p210 BCR-ABL and individual GFP þ clones were sorted by flow cytometry. Of the 60 individual clones, two were found to express significant levels of BCR-ABL by Western blots (AD4 and AC42) ( Figure 2a ) and were selected for functional analyses. These cells were continuously maintained in the presence of LIF and tetracyclin-HCl (TET), which inhibited the expression of STAT3F. AD4 and AC42 clones were first tested for their differentiation ability in liquid cultures in the presence of TET. Both BCR-ABLexpressing clones, as compared to uninfected GS2 cells, remained undifferentiated during 48 h when grown without LIF (Figure 2c ). However, upon removal of TET from the cell culture medium leading to STAT3F expression, both BCR-ABL-expressing ES clones underwent morphological differentiation ( Figure 2c ). To confirm the role of STAT3 inhibition in this phenomenon, EMSA were performed with cells grown in the presence and in the absence of TET for 48 h. 
Reversal of STAT3 activation induces differentiation towards hematopoietic lineage
To determine if the modulation of activated STAT3 levels could have any impact on the hematopoietic potential of ES cells, we performed hematopoietic progenitor assays using the GS2 cells and their BCR-ABL-expressing counterparts. Upon induction of differentiation by LIF deprivation, ES cells were cultured either in the presence or in the absence of TET both during generation of EB's in liquid culture and during hematopoietic clonogenic assays. When these experiments were performed in the presence of TET (STAT3 constitutively active), both BCR-ABL-expressing ES clones AD4 ( Figure 3a ) and AC42 (data not shown) exhibited a major decrease in their hematopoietic progenitor potential as compared to parental GS2 cells. This correlated with an increased number of secondary EB's observed in all dishes (Figure 3b ). Upon TET withdrawal (allowing inhibition of STAT3 activation), both BCR-ABL-expressing ES clones generated a significantly higher number of hematopoietic progenitors (Po0.01), whereas the numbers of progenitors obtained from the parental GS2 clones did not statistically change in the presence or in the absence of TET (Figure 3a) .
We next wished to confirm the hematopoietic phenotype of the cell populations generated in the presence or absence of activated STAT3. In all BCR-ABL-expressing ES cells grown in the presence of TET, the numbers of hematopoietic cells with evidence of erythroid or megakaryocytic differentiation patterns were low as compared to control cells (Table 1) . Conversely, BCR-ABL and GS2 clones grown in the absence of TET generated, in several experiments, higher numbers of cells committed to specific hematopoietic lineages, with evidence of increased erythroid and megakaryocytic differentiation markers (Table 1) . Thus, these experiments confirmed the results obtained by the hematopoietic progenitor assays (Figure 3) .
To determine whether hematopoietic differentiation correlated with the molecular differentiation markers of ES cells, we analysed sequential expression of Oct4, Brachyury and bH1 globin transcripts by RT-PCR analysis in both GS2 cells and its BCR-ABL-expressing counterparts grown in the presence or in the absence of TET. As can be seen in Figure 4 , Oct4 transcripts, expressed in undifferentiated cells, were present at high levels during differentiation of BCR-ABL clones grown with TET, the removal of which induced a decrease of Oct4 in day 4 EBs. More importantly, Oct4 expression, which persisted in the hematopoietic progenitors originating from BCR-ABL-expressing clones as compared to control cells, was found to be decreased when the cells were grown in the absence of TET (Figure 4) . Conversely, Brachyury transcript, normally expressed upon differentiation of ES cells, was found to be present at low levels at day 4 of the differentiation in cells expressing BCR-ABL grown in the presence of TET. However, upon TET removal, Brachyury levels increased to reach those observed in parental ES cells. Finally, bH1 globin expression was also found to be delayed in day 8 progenitors (i.e., day 13 of ES cells' differentiation) originating from BCR-ABL clones, this delayed expression being abrogated with the removal of TET from the culture medium (Figure 4) . Overall, these data suggested that expression of BCR-ABL favored ES cell renewal via constitutive and elective activation of STAT3, with reduction of the hematopoietic differentiation ability of these cells.
E-Increased levels of STAT3 expression and constitutive phosphorylation of STAT3 in Ph1 þ CD34 þ hematopoietic cells
The findings obtained in the murine ES cell model prompted us to study the expression of STAT3 protein levels in a series of human Ph1 þ hematopoietic cells. Western blot analysis revealed high levels of STAT3 expression in all CD34 þ Ph1 þ cells, as compared to control CD34 þ cells ( Figure 5 ). When analysed by the use of specific antiphosphotyrosine antibodies, STAT3 was found to be variably phosphorylated on Tyr705 residue in patients in chronic phase ( Figure 5, lanes 3-7) , whereas it was found to be phosphorylated in both patients with blast crisis (Figure 5, lanes 8 and 9) . On the other hand, the use of a specific anti-Serine-STAT3 antibody revealed a strong phosphorylation on Ser727 residue in all patients, a phosphorylation which has not 
Discussion
The Ph1 chromosome arises in a pluripotent hematopoietic stem cell with self-renewal ability (Holyoake et al., 1999) . BCR-ABL-expressing stem cells are characterized by their persistent differentiation ability towards all hematopoietic lineages during the chronic phase of the disease. In all experimental systems tested to date, it has been demonstrated that BCR-ABL was able to activate several signaling pathways, including those induced by hematopoietic growth factors (for a review, see Sawyers, 1999) . Indeed, it is well established that BCR-ABL induces a constitutive activation of STAT5, 1, 6 (Carlesso et al., 1996; Ilaria and Van Etten, 1996; Shuai et al., 1996; Ahmed et al., 1998) and to a lesser degree, that of STAT3 in hematopoietic cells (Ilaria and Van Etten, 1996) . The involvement of STAT5 in the induction of an antiapoptotic or proliferative phenotype has been demonstrated (Mui et al., 1996) . Among the different forms of STAT molecules activated by BCR-ABL, only STAT5 has been shown to be clearly required for the antiapoptotic potential of the chimeric oncogene (Nieborowska-Skorska et al., 1999; Sillaber et al., 2000) . STAT3 is the latent transcription factor normally activated by LIF, IL6 and OSM (Pellegrini and Dusanter-Fourt, 1997) . Self-renewal of the ES cells under the influence of LIF has been recently shown to be mediated by the activation of STAT3 (Niwa et al., 1998) via gp130 receptor (Ernst et al., 1999) . STAT3 is activated by LIF, whose action is mediated via heterodimerization of two members of the class I receptors, the low-affinity LIF receptor and gp130 (Boeuf et al., 1997) . Gp130 triggers the activation of Janus kinases (JAKs), which then leads to the phosphorylation of STAT3 on Tyr705 residue, allowing STAT3 homo-or heterodimerization and nuclear translocation. STAT3 full transcriptional activity also requires phosphorylation on Ser727 residue, which provides a degree of modulation of the gene activation induced by the Tyr705 phosphorylation (Zhang et al., 1995) .
The enforced expression of a dominant-negative form of STAT3 in ES cells induces a massive differentiation phenotype and unresponsiveness to LIF (Niwa et al., 1998) . Constitutive activation of STAT3 has been demonstrated in many tumor samples such as multiple myeloma, Hodgkin's disease or other lymphomas Karras et al., 2000; Kube et al., 2001) . STAT3 also plays an antiapoptotic role through upregulation of the Bcl-2 family of molecules while systemic abrogation of the STAT3 gene in the germ line leads to embryonic lethality (Takeda et al., 1997) . Introduction of antisense STAT3 or dominantnegative STAT3 in cell lines derived from multiple myeloma (Catlett-Falcone et al., 1999), squamous cell carcinomas (Grandis et al., 2000) and melanomas (Niu et al., 1999) has been shown to induce apoptosis. The activation of STAT3 by BCR-ABL has been demonstrated so far only in a single study using the Ba/F3 cell line (Ilaria and Van Etten, 1996) and no study has been reported concerning the activation of STAT3 in other cell contexts and in primary CML cells.
In CML, little is known about the mechanisms of expansion of the BCR-ABL-expressing leukemic clone. A rare but consistently detectable quiescent BCR-ABLpositive CD34 þ pluripotent hematopoietic stem cell population has recently been described in patients with CML (Holyoake et al., 1999) . This population could respond with a proliferative advantage to low concentrations of cytokines as compared to the normal hematopoietic cells, with expansion of the Ph1 þ clone (Holyoake et al., 2001 ). The signaling pathways by which Ph1 þ clone expands and undergoes self-renewal remain largely unknown. Accordingly, the potential mechanisms of leukemic stem cell renewal in BCR-ABLexpressing cells have not been studied so far. In the context of ES cells, the role of STAT3 in the promotion of self-renewal of ES cells has been well established. Similarly, the role of STAT3 activation in the selfrenewal of normal hematopoietic stem cells has not been established but the involvement of gp130 activation in promoting hematopoietic stem cell renewal divisions has recently been suggested (Audet et al., 2001) .
The strategy that we have used in this work allowed us to study BCR-ABL expression in a context of nontransformed primitive pluripotent stem cell. Our results provide evidence that in the context of ES cells, BCR-ABL can substitute for the action of LIF by maintenance of an undifferentiated phenotype despite LIF deprivation through a constitutive activation of STAT3. We demonstrate that this activation is selectively responsible for the inhibition of differentiation since inhibition of endogenous STAT3 expression with an inducible STAT3 protein with dominant-negative activity allows morphological differentiation of BCR-ABL-expressing ES cells. More interestingly, we show that the reversal of constitutive STAT3 activation favors hematopoietic differentiation in BCR-ABL-expressing GS2 cell clones. This suggests that in the ES cell lines, BCR-ABL is able to activate a major signaling pathway involved in the self-renewal of these cells, with evidence of reduced differentiation ability towards hematopoietic lineage. The differentiation towards other lineages appeared to be unperturbed, as we have observed in several experiments, EBs with pulsatile characteristics, suggesting cardiac muscle differentiation, with evidence of BCR-ABL expression by RT-PCR analysis (data not shown).
Our preliminary results by the use of patient samples are consistent with an accumulation and constitutive activation of STAT3 in CD34 þ hematopoietic stem cells from patients with Ph1 þ CML at diagnosis. Interestingly, the major and most consistent finding was the constitutive STAT3 phosphorylation at Ser727 residue, with a less marked Tyr705 phosphorylation. The functional significance of these findings at the level of Ph1 þ hematopoietic stem cell renewal is currently unknown. A direct role for STAT3 activation in the progression of Ph1 þ clone to blast crisis remains to be established. One of the possible mechanisms of increased STAT3 transcription could be accomplished by STAT3 itself, which has been shown to induce its own transcription (Ichiba et al., 1998) . Studies are ongoing in our laboratory to establish the functional role of STAT3 activation in Ph1 þ primitive hematopoietic stem cells.
Phenotypic effects of BCR-ABL have recently been studied in ES cell models (Era and Witte, 2000; Perlingeiro et al., 2001; Peters et al., 2001) . The myeloid expansion potential of the oncogene was shown to be activated when BCR-ABL expression was induced at day 5 of ES cell differentiation (Era and Witte, 2000) . BCR-ABL transfer in ES cells was also shown to generate leukemogenic cell lines or a lympho-myeloid hematopoiesis in vivo but only when BCR-ABL gene transfer was performed at the EB-5 stage of ES cell differentiation Peters et al., 2001 ). Thus, a potential STAT activation by BCR-ABL at the level of ES cells could not be evaluated in these studies. Our study provides evidence showing that BCR-ABL specifically activates STAT3 in the context of ES cells with no evidence of activation of STAT5 (data not shown), which is the most common STAT target in BCR-ABL-expressing hematopoietic cells (Ilaria and Van Etten, 1996; Ahmed et al., 1998) . Thus, this specific activation of STAT3 (but not that of STAT5 or STAT1), the major self-renewal molecule in the context of ES cells, by BCR-ABL is possibly not coincidental.
In summary, the conditional STAT3-ES cell model that we established is a unique tool to study self-renewal and differentiation events in the presence of the continuous expression of the BCR-ABL oncogene, by the use of gene array strategies. The ES cell model allowed also to pinpoint to the possible involvement of STAT3 in the human CML. The evaluation of the functional role of STAT3 activation in Ph1 þ hematopoietic cells will require the use of retroviral gene transfer strategies of dominant-negative forms of STAT3 gene in highly purified cell populations followed by functional hematopoietic stem cell assays.
Materials and methods
Cell culture
The 129/SV-derived CCE ES cell line and the GS2 ES cell line were cultured as previously described (Keller et al., 1993; Niwa et al., 1998) and supplemented with LIF (1000 U/ml). GS2 cell line was maintained in the absence of feeder cells in Glasgow modification of Eagle medium (GMEM, Life Technologies), and maintained in the continuous presence of tetracyclineHCl (TET) (Niwa et al., 1998) . This cell line contains a tetracycline-regulated dominant-negative form of STAT3 cDNA (STAT3F) with a 50% reduction of endogenous STAT3 expression upon TET removal, as detailed elsewhere (Niwa et al., 1998) .
Samples from CML patients and normal donors
Light-density CML cells were obtained using Ficoll-Hypaque gradients from patients with chronic phase at diagnostic (five patients), or during blastic phase (two patients). Control samples included normal bone marrow (n ¼ 1), mobilized peripheral blood (n ¼ 1) and cord blood (n ¼ 2). Cells were subjected to a standard CD34 þ immunomagnetic beads separation using the mini MACS system following the manufacturer's recommendations (Miltenyi Biotec, Auburn, CA, USA). CD34 þ cells were cryopreserved in liquid nitrogen. The purity of CD34 þ cells was more than 95% in all cases. For Western blot analyses, cryopreserved CD34 þ cell samples were thawed and cultured for 24-48 h in RPMI 1640 medium (GIBCO, UK) containing 15% FCS.
BCR-ABL vectors
The pKJ1 is an expression plasmid containing NeoR gene under the control of mouse PGK-1 promoter (Adra et al., 1987) . The pKJ1-p210 vector was constructed by inserting the B7 kb BCR-ABL c-DNA into the pKJ-1 vector, with removal of the NeoR sequences. MIGR-IRES-GFP vector and its counterpart expressing BCR-ABL were previously described (Pear et al., 1998) .
BCR-ABL gene transfer
Gene transfer into the CCE ES cells was accomplished using pKJ1-p210 vector coelectroporated along with pM1C Neo vector (20:1 ratio) using a Cell-ject electroporator (Eurogentec, Brussels, Belgium). Individual NeoR-expressing ES cell clones were amplified and BCR-ABL-expressing clones were selected by Western blot analysis. To generate BCR-ABL-expressing GS2 cell clones, we have used a retroviral gene transfer strategy using MIGR-p210 BCR-ABL retrovirus using a VSVG pseudotyping strategy as previously described (Dugray et al., 2001) .
ES cell differentiation
To visualize the differentiation patterns of CCE and GS2 cells as well as that of their BCR-ABL-expressing counterparts, we have used a short-term culture technique. Cells deprived of LIF (CCE clones) and/or TET (GS2 clones) were plated in untreated culture dishes and differentiation pattern was evaluated microscopically each day until day 3. To determine the status of STAT3 activation before and after the cell culture in the conditions above, nuclear cell extracts were obtained for electrophoretic mobility shift analysis (EMSA).
Hematopoietic progenitor cell assays
These assays were performed in methylcellulose as previously described using GS2-BCR-ABL clones (Keller et al., 1993) . Embryoid bodies (EBs) from GS2 cells were obtained by using a liquid EBs culture strategy (Kennedy et al., 1997) . Hematopoietic colonies were generated by plating EBs in 1% methylcellulose in Iscove modified Dulbecco medium (IMDM) including 10% fetal calf serum (FCS), 10% bovine serum albumine (BSA) (Sigma), insulin (10 g/ml), monothioglycerol (MTG) (450 m), erythropoietin (Epo) (5 U/ml), murine stem cell factor (SCF) (5 U/ml), interleukin (IL)-1 (1000 U/ml), IL-3 (50 U/ml), IL-6 (10 ng/ml) and granulocyte-colony stimulating factor (G-CSF) (10 ng/ml).
Hematopoietic differentiation from ES cells was also examined in cells derived from day À5 EBs, which were suspended in IMDM and cultured in the presence of the same combination of cytokines as above for 8 days. Cells generated in this manner were counted and processed for either cytological or flow cytometry analyses.
PCR analyses
To detect successful BCR-ABL integration in individual ES cell clones, PCR analysis was performed at the DNA level. To determine expression of differentiation associated markers in ES cells, total RNA was extracted with Trizol (GIBCO, UK), as recommended by the manufacturer. RNA (1 mg) was used for each RT reaction. RNA was reverse-transcribed with M-MLV reverse transcriptase with random hexanucleotide primers (Boehringer) as recommended by the supplier (Life Technologies). PCR was performed in a final volume of 50 ml in the presence of 2.5 U of Taq polymerase (ATGC, Noisy-leGrand, France), 400 nm of sense and antisense primers and 250 m dNTPs in the appropriate 1 Â PCR buffer (ATGC). Primers and protocols used for the PCR reactions were as previously published (Keller et al., 1993) . PCR was performed using a Perkin-Elmer 2400 apparatus.
Western blots
Whole cell extracts (30 mg) were boiled in Laemmli buffer, loaded on a 7.5% SDS-polyacrylamide gel, separated by electrophoresis, and electrotransferred onto nitrocellulose filters. Blots were incubated in 5% low-fat milk, 10 mm Tris, 137 mm NaCl, 0.1% Tween (blocking solution) for 2 h. Abl antibody was purchased from Oncogene (Oncogene, Cambridge, MA, USA) and phospho-Tyr705 STAT3, phosphoSer727 STAT3 and total STAT3 were purchased from New England Biolabs (New England Biolabs, Beverly, MA, USA). Antibodies were diluted 1 : 1000 (Abl or STAT3 antibodies) or 1 : 500 (phospho-Tyr705 and phospho-Ser727 antibodies) overnight in PBS Tween with 5% low-fat milk. After washing for 1 h, the secondary horseradish peroxidase-coupled antimouse (Abl) or rabbit (STAT3) antibodies diluted at 1 : 5000 were applied to the membrane in PBS Tween with 5% low-fat milk and rewashed. Blotting was revealed using an enhanced chemiluminescence (ECL) kit (Amersham Corp. Arlington Heights, IL, USA).
EMSA
Permanently growing ES cells transfected with NeoR, MIGR or BCR-ABL constructs were washed in serum-free medium and nuclear extracts were prepared from each clone. An aliquot of each clone was also incubated with interferon (IFN)-g (1000 U/ml), LIF and granulocyte-monocyte (GM)-CSF (50 ng/ml) at 371C for 15 min, and nuclear extracts were prepared as controls for STAT1, STAT3 and STAT5 activation. For EMSA analysis, nuclear extracts were incubated with 10-15 fmol of a 32 P-labeled oligonucleotide as a probe. Each oligonucleotide probe (SIEm67, 5 0 -CATTTCCCGTAAATC-3 0 ; IRF1-GAS 5 0 -GATC-CATTTCCCCGAAATGA-3 0 ; b-Casein-GAS 5-AGATTC-TAGGAATTCAAATC-3 0 ) was end-labeled using T4 polynucleotide kinase to a specific activity of 8000 c.p.m./fmol as previously described (Gouilleux et al., 1995) . For supershift analysis, a 1 : 15 or 1 : 20 dilution of antibody was added for an additional 45 min at 41C.
Flow cytometry analysis
Rat monoclonal antibodies that recognize murine hematopoietic cell-surface antigens were all purchased from Pharmingen (San Diego, CA, USA). Phycoerythrin (PE)-conjugated anti-CD41 and TER-119 antibodies were used in the presence of irrelevant control antibodies.
Hematopoietic cells obtained in liquid cultures from day À5 EBs were washed in PBS, mechanically dissociated with 200 ml pipet tips and filtered using 40 mm Millipore units. Cells were incubated for 20 min at 41C with each antibody. After washing, they were suspended in PBS 5% FCS supplemented with 7-amino-actinomycin D (7-AAD, Sigma) to exclude dead cells. Cell-surface labeling was analysed by flow cytometry on a FACScan (Becton-Dickinson, San Jose, CA, USA). Data were acquired from 10 4 cells in list mode and analysed with CellQuest software (Becton-Dickinson).
Statistical analysis
The number of hematopoietic progenitors obtained from BCR-ABL-expressing cells and parental GS2 cells was compared using a Wilcoxon two-sided test.
